Basic and Clinical Studies of Transferrin-Adriamycin Conjugates: Mechanisms for a New Approach to Drug Targeting

  • W. P. Faulk
  • D. S. Torry
  • H. Harats
  • J. A. McIntyre
  • C. G. Taylor
Part of the NATO ASI Series book series (NSSA, volume 7)


Research in drug targeting to cancer cells is almost exclusively limited to monoclonal antibodies. The clinical use of monoclonal antibodies is frought with problems. Three of the most serious problems are antigen shedding, sensitization of the patient to mouse immunoglobulins, and mutation of the antigenic target. Antigen shedding is the antibody-induced disappearance of antigens from cell membranes. Drugs cannot exert cytotoxic effects if their antibody carriers are shed with antigen. The second problem is sensitization of patients to mouse immunoglobulins. Mouse proteins are antigenically foreign to the human immune system. Some patients mount hypersensitivity reactions to mouse immunoglobulins and are in danger of developing anaphylactic responses. The magnitude of this problem is shown by the finding that 50% of leukemia and lymphoma patients treated with monoclonal antibodies develop hypersensitivity reactions.1 The third problem with monoclonal antibodies relates to their restricted specificity. This is represented by cells that lose or mutate their surface antigens. Such cells are no longer recognized by cell-specific monoclonals and consequently acquire the ability to escape the anti-cancer effects of drugs conjugated to monoclonal antibodies.


Acute Myelocytic Leukemia Transferrin Receptor Tritiated Thymidine Mouse Immunoglobulin Acute Myelogenous Leukemia Cell 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    R. Levy and R.A. Miller, Tumor therapy with monoclonal antibodies, Fed. Proc. 42: 2650, (1983).PubMedGoogle Scholar
  2. 2.
    W.P. Faulk and G.M.P. Galbraith, Trophoblast transferrin and transferrin receptors in the host-parasite relationship of human pregnancy, Proc. Roy. Soc. London B. 204: 83, (1979).CrossRefGoogle Scholar
  3. 3.
    G.M.P. Galbraith, R.M. Galbraith and W.P. Faulk, Transferrin binding by human lymphoblastoid cell lines and other transformed cells, Cell. Immunol. 49: 215, (1980).PubMedCrossRefGoogle Scholar
  4. 4.
    R.M. Galbraith and G.M.P. Galbraith, Expression of transferrin receptors on mitogen-stimulated human peripheral blood lymphocytes: relation to cellular activation and related metabolic events, Immunology 44: 703, (1981).PubMedGoogle Scholar
  5. 5.
    C.J.G. Yeh, C.G. Taylor and W.P. Faulk, Transferrin binding by peripheral blood mononuclear cells in human lymphomas, myelomas and leukemias, Vox Sang. 46: 217, (1984).PubMedCrossRefGoogle Scholar
  6. 6.
    J.E. Shindelman, A.E. Ortmeyer and H.H. Sussman, Demonstration of the transferrin receptor in human breast cancer tissue. Potential marker for identifying dividing cells, Int. J. Cancer 27: 329, (1981).PubMedCrossRefGoogle Scholar
  7. 7.
    U. Testa, Transferrin receptors: structure and function, Curr. Top. Hematol. 5: 127, (1985).PubMedGoogle Scholar
  8. 8.
    W.P. Faulk, B.L. Hsi and P.J. Stevens, Transferrin and transferrin receptors in carcinoma of the breast, Lancet ii: 390, (1980).CrossRefGoogle Scholar
  9. 9.
    C.J.G. Yeh and W.P. Faulk, Killing of human tumor cells in culture with adriamycin conjugates of human transferrin, Clin. Immunol. Immunopathol. 32: 1, (1984).PubMedCrossRefGoogle Scholar
  10. 10.
    C.J.G. Yeh, C.G Taylor and W.P. Faulk, Targeting of cytotoxic drugs by transferrin receptors: Selective killing of acute myelogenous leukemia cells, Prot. Biol. Fluids 42: 441, (1984).Google Scholar
  11. 11.
    I. Sun, P. Navas, F. Crane, D.J. Morre and H. Low, NADH diferric transferrin reductase in liver plasma membrane, J. Biol. Chem. 262: 15915, (1987).PubMedGoogle Scholar
  12. 12.
    I. Sun, Crane F.L., C. Grebing and H. Low, Properties of a transplasma membrane electron transport system in HeLa cells, J. Bioenerget. Biomembr. 16: 583, (1984).CrossRefGoogle Scholar
  13. 13.
    C.J.G. Yeh, M. Papamichail and W.P. Faulk, Loss of transferrin receptors following induced differentiation of HL-60 promyelocytic leukemia cells, Exp. Cell Research 138: 429, (1982).CrossRefGoogle Scholar
  14. 14.
    W.P. Faulk, A. Temple, R.E. Lovins and N. Smith, Antigens of human trophoblasts: A working hypothesis for their role in normal and abnormal pregnancies, Proc. Natl. Acad. Sci. (USA) 75: 1947, (1978).CrossRefGoogle Scholar
  15. 15.
    B. Ecarot-Charrier, V.L. Grey, A. Wilcyznska and H.M. Schulman, Can. J. Biochem. 58: 418, (1980).PubMedCrossRefGoogle Scholar
  16. 16.
    E.H. Morgan, Biochem. Biophys. Acta 762: 488, (1983).Google Scholar
  17. 17.
    A. Dautry-Varsat, A. Crechanover and H.F. Lodish, pH and the recycling of transferrin during receptor mediated endocytosis, Proc. Natl. Acad. Sci. (USA) 80: 2258, (1983).CrossRefGoogle Scholar
  18. 18.
    R.D. Klausner, G. Ashwell, J. Van Renswoude, J.B. Hartford and K.R. Bridges, Binding of apotransferrin to k562 cells: explanation of the transferrin cycle, Proc. Natl. Acad. Sci. (USA) 80: 2263, (1983).CrossRefGoogle Scholar
  19. 19.
    G.J. Anderson, A. Macherras, L.W. Powell and J.W. Halliday, Improved purification of the human placental transferrin receptor and a novel immunoradiometric assay for receptor protein, Biochimica et Biophysica Acta 884: 225, (1986).PubMedCrossRefGoogle Scholar
  20. 20.
    I.R. Van Driel, P.A. Stearne, B. Grego, R.J. Simpson and J.W. Coding, The receptor for transferrin on murine myeloma cells: One-step purification based on its physiology, and partial amino acid sequence, J. Immunol. 133: 3220, (1984).PubMedGoogle Scholar
  21. 21.
    C.J.G. Yeh, B.L. Hsi, M. Samson, J.A. McIntyre, J.P. Breittmeyer and M. Fehlmann, Monoclonal antibodies (GB16, GB18, GB19, GB22) raised against human placental microvilli recognize the transferrin receptor, Placenta 8: 627, (1987).PubMedCrossRefGoogle Scholar
  22. 22.
    H. Low, C. Grebing, A. Lindgren, M. Tally, I. Sun and F. Crane, Involvement of transferrin in the reduction of iron by the transplasma membrane electron transport system, J. Bioenerget. Biomembr. 19: 535, (1987).Google Scholar
  23. 23.
    H. Low, I. Sun, P. Navas, C. Grebing, F. Crane and D.J. Morre, Transplasmalemma electron transport from cells is part of a diferric transferrin reductase system, Biochem. Biophy. Res. Com. 139: 1117, (1986).CrossRefGoogle Scholar
  24. 24.
    F. Crane, I. Sun, M.G. Clark, C. Grebing and H. Low, Transplasmamembrane redox systems in growth and development, Biochem. Biophy. Acta 811: 233, (1985).CrossRefGoogle Scholar
  25. 25.
    I. Sun, R. Garcia-Canero, W. Liu, W. Toole-Simms, F. Crane, D.J. Morre and H. Low, Diferric transferrin reduction stimulates the Na+/H+ antiport of HeLa cells, Biochem. Biophy. Res. Com. 145: 467, (1987).CrossRefGoogle Scholar
  26. 26.
    I. Sun, P. Navas, F. Crane, D.J. Morre and H. Low, Differic transferrin reductase in the plasma membrane is inhibited by adriamycin, Biochem. Internatl. 14: 119, (1987).Google Scholar
  27. 27.
    P. Navas, I. Sun, D.J. Morre and F. Crane, Decrease of NADH in HeLa cells in the presence of transferrin or ferricyanide, Biochem. Biophy. Res. Com. 135: 110, (1986).CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1988

Authors and Affiliations

  • W. P. Faulk
    • 1
  • D. S. Torry
    • 1
  • H. Harats
    • 1
  • J. A. McIntyre
    • 1
  • C. G. Taylor
    • 2
  1. 1.Methodist Center for Reproduction and Transplantation ImmunologyIndianapolisUSA
  2. 2.Pembury HospitalTunbridge Wells, KentUK

Personalised recommendations